Assessing Oxygenation Response to Eribulin in a Patient with Recurrent Breast Cancer after Resistance to Endocrine Therapy

Ueda, Shigeto; Sendo, Toshiaki; Yamane, Toshimi; Kuji, Ichiei

doi:10.4172/2167-7964.1000250

Cited by 1 publication

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the FMISO-PET/CT results confirmed corresponding reductions in intracellular hypoxia. Together, these two reports [51,52] showed that, in breast cancer patients, eribulin treatment is associated with increased tumor oxygenation and decreased intracellular hypoxia. That such effects in breast cancer patients are driven by the increased tumor microvessel density seen in preclinical models [14] is suggested by the results of Yardley and colleagues [53], who showed statistically significant increases in anti-CD31 staining for endothelial cells in patient tumor biopsies taken after eribulin-cyclophosphamide neoadjuvant treatment relative to pretreatment biopsies.…”

Section: Clinical Support For Eribulin's Non-mitotic Mechanisms Of Acmentioning

confidence: 82%

“…To conclusively demonstrate that increased oxygenation of the tumor as a whole was associated with decreased intracellular hypoxia, Ueda and colleagues [52] used 18 F-fluoromisonidazole-positron emission tomography/computed tomography (FMISO-PET/CT) as well as DOSI to measure both intracellular hypoxia and overall tumor oxygen saturation, respectively, after three cycles of eribulin treatment of a patient with breast cancer. The DOSI results confirmed that, similar to their earlier findings after a single eribulin dose [51], eribulin treatment for three cycles (6 doses) also resulted in increased overall tumor oxygen saturation.…”

Section: Clinical Support For Eribulin's Non-mitotic Mechanisms Of Acmentioning

confidence: 99%

“…xenografts [14] • Increased perfusion in STS xenograft models [6,20] • Reduced expression of genes regulating hypoxia [14] • Improved antitumor activity for subsequent treatments [14,21] • Significant decreases in deoxygenated hemoglobin with corresponding increases in oxygen saturation in breast tumors after eribulin treatment [51] • Decreased intracellular hypoxia in a breast tumor after eribulin treatment (case study) [52] • Significant increases in endothelial cell staining in tumor biopsies after eribulin/cyclophosphamide neoadjuvant treatment [53] Reversal of EMT (breast cancer, OSCC)…”

Section: Clinical Support For Eribulin's Non-mitotic Mechanisms Of Acmentioning

confidence: 99%

See 2 more Smart Citations

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications

Cortés

Schöffski

Littlefield

2018

Cancer Treatment Reviews

View full text Add to dashboard Cite

Eribulin mesylate (eribulin) is a synthetic analogue of the marine-sponge natural product halichondrin B. Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell types in vitro and in vivo, and is used for the treatment of certain patients with advanced breast cancer or liposarcoma who are refractory to other treatments. The antiproliferative effects of eribulin have long been attributed to its antimitotic activities. Unlike other microtubule-targeting agents, eribulin inhibits microtubule polymerization through specific plus end binding, thus interfering with microtubule dynamic instability. Non-mitotic effects of eribulin on tumor biology have also been established in laboratory settings including: tumor vasculature remodeling, increased vascular perfusion, reduced hypoxia, and phenotypic changes involving reversal of epithelial-to-mesenchymal transition (EMT), resulting in reduced capacities for migration, invasion, and seeding lung metastases in experimental models. Preclinical data suggest that increased perfusion following eribulin treatment improves delivery of subsequent drugs. Supporting evidence for eribulin's non-mitotic effects in the clinical setting include increased tumor oxygen saturation, reduced hypoxia, phenotype changes consistent with EMT reversal, and genotype changes consistent with shifts from nonendocrine-responsive, luminal B, to endocrine-responsive, luminal A, breast cancer subtypes. Finally, potential biomarkers for eribulin response have been established based on tumor-phenotype and gene-expression profiles. Overall, preclinical and clinical data support both antimitotic and non-mitotic mechanisms of eribulin that may underlie the survival benefit observed in various clinical trials.

show abstract

Section: Clinical Support For Eribulin's Non-mitotic Mechanisms Of Acmentioning

confidence: 82%

Section: Clinical Support For Eribulin's Non-mitotic Mechanisms Of Acmentioning

confidence: 99%

Section: Clinical Support For Eribulin's Non-mitotic Mechanisms Of Acmentioning

confidence: 99%

See 1 more Smart Citation

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications

Cortés

Schöffski

Littlefield

2018

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

Assessing Oxygenation Response to Eribulin in a Patient with Recurrent Breast Cancer after Resistance to Endocrine Therapy

Cited by 1 publication

References 11 publications

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications

Contact Info

Product

Resources

About